EMAIL THIS PAGE TO A FRIEND

Molecular psychiatry

FGF-21, a novel metabolic regulator, has a robust neuroprotective role and is markedly elevated in neurons by mood stabilizers.


PMID 24468826

Abstract

Fibroblast growth factor-21 (FGF-21) is a new member of the FGF super-family and an important endogenous regulator of glucose and lipid metabolism. It has been proposed as a therapeutic target for diabetes and obesity. Its function in the central nervous system (CNS) remains unknown. Previous studies from our laboratory demonstrated that aging primary neurons are more vulnerable to glutamate-induced excitotoxicity, and that co-treatment with the mood stabilizers lithium and valproic acid (VPA) induces synergistic neuroprotective effects. This study sought to identify molecule(s) involved in these synergistic effects. We found that FGF-21 mRNA was selectively and markedly elevated by co-treatment with lithium and VPA in primary rat brain neurons. FGF-21 protein levels were also robustly increased in neuronal lysates and culture medium following lithium-VPA co-treatment. Combining glycogen synthase kinase-3 (GSK-3) inhibitors with VPA or histone deacetylase (HDAC) inhibitors with lithium synergistically increased FGF-21 mRNA levels, supporting that synergistic effects of lithium and VPA are mediated via GSK-3 and HDAC inhibition, respectively. Exogenous FGF-21 protein completely protected aging neurons from glutamate challenge. This neuroprotection was associated with enhanced Akt-1 activation and GSK-3 inhibition. Lithium-VPA co-treatment markedly prolonged lithium-induced Akt-1 activation and augmented GSK-3 inhibition. Akt-1 knockdown markedly decreased FGF-21 mRNA levels and reduced the neuroprotection induced by FGF-21 or lithium-VPA co-treatment. In addition, FGF-21 knockdown reduced lithium-VPA co-treatment-induced Akt-1 activation and neuroprotection against excitotoxicity. Together, our novel results suggest that FGF-21 is a key mediator of the effects of these mood stabilizers and a potential new therapeutic target for CNS disorders.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

02685
Lithium atomic spectroscopy standard concentrate 1.00 g Li, for 1 l standard solution, 1.00 g/L, analytical standard
ClLi
746460
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ACS reagent, ≥99%
ClLi
793620
Lithium chloride, anhydrous, free-flowing, Redi-Dri, ReagentPlus®, 99%
ClLi
L4408
Lithium chloride, BioXtra, ≥99.0% (titration)
ClLi
62476
Lithium chloride, BioUltra, for molecular biology, anhydrous, ≥99.0% (AT)
ClLi
L9650
Lithium chloride, for molecular biology, ≥99%
ClLi
429457
Lithium chloride, anhydrous, beads, −10 mesh, 99.998% trace metals basis
ClLi
449881
Lithium chloride, anhydrous, beads, −10 mesh, ≥99.9% trace metals basis
ClLi
203637
Lithium chloride, powder, ≥99.99% trace metals basis
ClLi
HT-LICLSLUG
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
751898
Lithium chloride, anhydrous, chunks, 99.99% trace metals basis
ClLi
L7026
Lithium chloride solution, 8 M, for molecular biology, ≥99%
ClLi
694576
Lithium chloride solution, 1 M in 1,3-dimethyl-2-imidazolidinone
ClLi
62483
Lithium chloride solution, 1 M in glacial acetic acid
ClLi
62481
Lithium chloride solution, 1 M in ethanol
ClLi
667544
Lithium chloride solution, 0.5 M in anhydrous tetrahydrofuran
ClLi
LCL30
Lithium chloride solution, 2 M in ethanol
ClLi
601489
Lithium-7Li chloride, 99 atom % 7Li, 99% (CP)
Cl7Li